Evidence map›Paper›PMID 42238016›Full record

ArticleOncology research2026

Impact of Germline

Renata Pacholczak-Madej, Mirosława Püsküllüoğlu, Anna Polakiewicz-Gilowska, Małgorzata Pieniążek, Iveta Kolářová, Miroslava Malejčíková, Lenka Rušinová, Miloš Holánek, Renata Soumarová, Karolina Winsko-Szczęsnowicz and 17 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Renata Pacholczak-MadejDepartment of Gynecological Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków Branch, Kraków, Poland.ORCID https://orcid.org/0000-0002-6535-4841
Mirosława PüsküllüoğluDepartment of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków Branch, Kraków, Poland.
Anna Polakiewicz-GilowskaBreast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland.
Małgorzata PieniążekLower Silesian Comprehensive Cancer Center, Wrocław Medical University, Wrocław, Poland.
Iveta KolářováDepartment of Oncology and Radiotherapy, Faculty of Medicine in Hradec Králové and University Hospital in Hradec Králové, Charles University, Hradec Králové, Czech Republic.
Miroslava MalejčíkováOncology Clinic of LFUK, National Cancer Institute, Bratislava, Slovakia.
Lenka RušinováDepartment of Oncology, Stefan Kukura Hospital Michalovce, Michalovce, Slovakia.
Miloš HolánekDepartment of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, and Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Renata SoumarováDepartment of Oncology, Third Faculty of Medicine, Charles University, University Hospital Kralovské Vinohrady, Prague, Czech Republic.
Karolina Winsko-SzczęsnowiczDepartment of Clinical Oncology, Maria Sklodowska-Curie Bialystok Oncology Center, Białystok, Poland.
Justyna ŻubrowskaDepartment of Clinical Oncology, Holy Cross Cancer Center, Kielce, Poland.
Aleksandra KoniecznaDepartment of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Agnieszka MłodzińskaDepartment of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Daniel KrejčíDepartment of Oncology, First Faculty of Medicine, Charles University in Prague, and Bulovka University Hospital, Prague, Czech Republic.
Iwona DanielewiczDepartment of Oncology and Radiotherapy, Szpitale Pomorskie sp. z o.o., Gdynia, Poland.
Magdalena Szymanik-ReskoDepartment of Oncology and Radiotherapy, Szpitale Pomorskie sp. z o.o., Gdynia, Poland.
Tomasz CiszewskiDepartment of Metabolic Diseases and Immuno-Oncology, Medical University of Lublin, Lublin, Poland.
Maja Lisik-HabibDepartment of Proliferative Diseases, Nicolaus Copernicus Multidisciplinary Centre for Oncology and Traumatology, Lodz, Poland.
Anika PękalaDepartment of Proliferative Diseases, Nicolaus Copernicus Multidisciplinary Centre for Oncology and Traumatology, Lodz, Poland.
Hana ŠtudentováDepartment of Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
Jan ŠustrDepartment of Oncology and Radiotherapy, Faculty of Medicine in Pilsen, Charles University, and University Hospital Pilsen, Plzen, Czech Republic.
Bogumiła Czartoryska-ArłukowiczDepartment of Clinical Oncology, Maria Sklodowska-Curie Bialystok Oncology Center, Białystok, Poland.
Aleksandra ŁackoLower Silesian Comprehensive Cancer Center, Wrocław Medical University, Wrocław, Poland.
Jolanta Smok-KalwatDepartment of Clinical Oncology, Holy Cross Cancer Center, Kielce, Poland.
Michał JarząbBreast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland.
Zuzana BielčikováDepartment of Oncology, First Faculty of Medicine, Charles University, and General University Hospital, Prague, Czech Republic.
Marcin KubeczkoBreast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BRCA1 ProteinBRCA2 ProteinCamptothecinGerm-Line MutationTriple Negative Breast NeoplasmsAdultAgedCzech RepublicFemaleHumansMiddle AgedPolandPrognosisRetrospective StudiesSlovakiaTreatment OutcomeBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanCamptothecinBRCA1/2 germline mutationsinternational multicenter cohortreal-world evidencesacituzumab govitecanTriple-negative breast cancer

Identifiers

PMID42238016
PMCPMC13227596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.